eIF2B Modulators for Integrated Stress Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases, leukodystrophies, cancers, inflammatory diseases, and metabolic disorders often fail to effectively modulate the integrated stress response (ISR) pathway, particularly by targeting the eIF2B complex, which is crucial for managing stress-related cellular processes.
Innovation Solution
Development of compounds, such as those represented by Formulas (I) and (II), which act as eIF2B modulators to activate eIF2B and attenuate the ISR signaling pathway, thereby treating diseases associated with impaired eIF2B function or activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If eIF2α is phosphorylated in response to stress signals, then cellular stress response is activated, but translation initiation is attenuated
Solution Approach 1:
The patent uses eIF2B modulators as intermediary compounds to regulate the balance between stress response activation and translation initiation. These small molecules act as mediators that can enhance eIF2B activity to counteract the inhibitory effect of phosphorylated eIF2α on translation, while preserving the protective stress response functions.
Solution Approach 2:
The invention changes the activity parameter of eIF2B through pharmacological modulation. By administering eIF2B activators, the patent alters the kinetic parameters of the GDP/GTP exchange reaction catalyzed by eIF2B, thereby adjusting the level of ternary complex formation and translation initiation rate without directly interfering with the phosphorylation signaling pathway.
2Productivity
If eIF2B activity is enhanced to promote translation, then protein synthesis increases, but cellular stress management capability may be compromised
Solution Approach 1:
The patent employs dynamic modulation of eIF2B activity through reversible small molecule binding rather than irreversible genetic modification. This allows the system to adaptively respond to changing cellular conditions, enhancing translation when needed while maintaining the ability to mount stress responses when challenged, creating a flexible and tunable regulatory system.
Solution Approach 2:
The invention leverages the existing feedback mechanisms of the ISR pathway. By modulating eIF2B activity, the compounds allow the cell to sense stress conditions and adjust translation accordingly, with the pathway's inherent feedback loops ensuring that stress management functions are preserved while productivity is enhanced under appropriate conditions.
3Reliability
If small molecule therapeutics target eIF2B to modulate ISR, then disease treatment potential is achieved, but selective targeting without off-target effects is challenging
Solution Approach 1:
The patent designs small molecules with specific structural features that target particular regions or conformations of eIF2B, achieving local interaction specificity. The compounds are engineered to bind to specific sites on the eIF2B complex (such as the catalytic core or regulatory sub-complex interfaces) to modulate its activity without interfering with other cellular proteins or pathways.
Data Source
AI summary
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.